+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 12Years +
All Genders
ID07355296

Testing BI 764198 Tablets for Adults and Adolescents with Various Proteinuric Kidney Diseases Compared to Placebo

Led by Boehringer Ingelheim · Updated on 2026-10-28

132

Participants Needed

154

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the medicine BI 764198 to see if it helps people with certain kidney conditions, including secondary focal segmental glomerulosclerosis, treatment-resistant primary minimal change disease, Alport Syndrome, and treatment-resistant primary membranous nephropathy. The study includes adults and adolescents with specific kidney diseases and aims to assess the medicines safety, tolerability, and effectiveness compared to a placebo. Participants are randomly assigned to one of two groups one group takes BI 764198 tablets and the other takes placebo tablets that look identical but do not contain medicine. They take one tablet daily for 20 weeks while continuing their usual kidney disease treatments. The chance of being assigned to the BI 764198 group is twice as high as being assigned to the placebo group. The study lasts about 7 months, during which participants attend six site visits and three phone calls. Doctors regularly collect urine and blood samples to measure protein levels and kidney function. They monitor health and any side effects, comparing results between the groups to evaluate the treatment. The primary outcome is the change in urine protein-to-creatinine ratio after 20 weeks.

CONDITIONS

Brief Title

PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease

Research Team

B

Boehringer Ingelheim

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here